Compare Infosys Limited (INFY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Travere Therapeutics Inc. Common Stock — how do they compare? Infosys Limited trades at $11.76 (market cap $44.92B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Infosys Limited is far larger — about 8.9× Travere Therapeutics Inc. Common Stock's market cap, and Infosys Limited pays a 4.59% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 26 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| INFY | TVTX | |
|---|---|---|
Market Cap | $44.92B | $5.02B |
Volume | 25,564,570 | 2,060,842 |
Sector | Technology | Health |
52-Week High | $20.22 | $67.52 |
52-Week Low | $10.49 | $26.79 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $42.66B | $5.15B |
Dividend Yield | 4.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.40, up 5.26% today, with a bullish technical signal driven by oversold RSI conditions. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 exceeding expectations. Revenue for 2025 was $19.28B, with a net income margin of 16.37%. Recent news highlights strategic AI collaborations with Columbia University and ABN Amro, positioning the firm for innovation-driven growth.
The outlook is cautiously optimistic, supported by solid profitability and strategic partnerships, but tempered by a mixed analyst consensus and potential net cash flow decline in 2026. Key risks include competitive pressures in IT services and macroeconomic sensitivity. The consensus price target of $11.48 suggests limited near-term upside from current levels.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
